Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...